FDA Brief

Warning letters Drugs

FDA warning letter to

Nowrez & Ismail Shukri Company

High riskIssued Jul 11, 2024Posted Aug 13, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.

What happened

FDA reviewed records the firm submitted after two requests for records under section 704(a)(4) of the FD&C Act, dated September 12, 2022, and February 26, 2024. FDA found significant CGMP violations for finished drugs: inadequate finished-product testing, inadequate stability testing, and no demonstrated testing of incoming isopropyl alcohol for methanol. FDA placed the firm on Import Alert 66-40 on July 3, 2024.

What FDA found

  1. FDA found the firm did not show adequate finished drug product testing, including identity and strength assay and microbiological testing, before release.

    21 CFR 211.165(a)
  2. FDA found the firm's stability program did not show ongoing chemical and microbiological testing to support the expiry period for products shipped after 2017.

    21 CFR 211.166(a)
  3. FDA found the firm did not test incoming isopropyl alcohol for methanol and relied solely on the supplier's certificate of analysis for identity testing.

    21 CFR 211.84(d)(1) and 211.84(d)(2)

What FDA wants

Respond in writing within 15 working days with what was done to correct violations and prevent recurrence; if not complete, give reasons and a completion schedule. FDA also recommends a qualified CGMP consultant and a six-system audit before resuming U.S. drug manufacturing.

Who should pay attention

  • brands and distributors buying OTC drugs from this manufacturer
  • importers of Jordan-made rubbing alcohol or OTC drugs
  • supplier-quality teams checking alcohol component testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk